Market Overview

UPDATE: Cantor Fitzgerald Maintains Life Technologies at Hold Following Test Results

Related LIFE
Mid-Afternoon Market Update: Eagle Bulk Shipping Falls Following $105 Million Liquidity Raise Announcement; Sky Solar Shares Jump
Mid-Day Market Update: Progress Software Drops On Weak Results; Medivation Shares Surge

Cantor Fitzgerald reiterated its Hold rating and $47 price target on Life Technologies (NASDAQ: LIFE).

Cantor Fitzgerald noted, "Earlier today, LIFE announced the launch of a CLIA-based, lung cancer risk stratification test for early stage lung cancer. The test (Pervenio Lung RS) was obtained through the acquisition of Pinpoint Genomics (July 25) and immediately leverages CLIA capabilities from the Navigenics acquisition (July 16). Based on currently available data, we are uncertain about the longer-term clinical utility of the test (other than to treat most early stage patients more aggressively), although we are turning positive on the tangible progress LIFE continues to make in building diagnostics capabilities."

Life Technologies closed at $48.92 on Tuesday.

Latest Ratings for LIFE

Mar 2016William BlairDowngradesOutperformMarket Perform
Dec 2015CitigroupInitiates Coverage onNeutral
Jun 2015JP MorganInitiates Coverage onOverweight

View More Analyst Ratings for LIFE
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Reiteration Intraday Update Analyst Ratings


Related Articles (LIFE)

View Comments and Join the Discussion!